Guardant Health Key Executives
This section highlights Guardant Health's key executives, including their titles and compensation details.
Find Contacts at Guardant Health
(Showing 0 of )
Guardant Health Earnings
This section highlights Guardant Health's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-20 | $-0.75 | $-0.62 |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $-0.55 | $-0.45 |
| Read Transcript | Q2 | 2024 | 2024-08-07 | $-0.57 | $-0.48 |
| Read Transcript | Q1 | 2024 | 2024-05-08 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-02-22 | $-0.93 | $-1.58 |
| Read Transcript | Q3 | 2023 | 2023-11-06 | $-0.93 | $-0.73 |
| Read Transcript | Q2 | 2023 | 2023-08-03 | $-1.25 | $-0.67 |
| Read Transcript | Q1 | 2023 | 2023-05-09 | $-1.26 | $-1.30 |
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
$48.30
Stock Price
$5.96B
Market Cap
2.02K
Employees
Redwood City, CA
Location
Financial Statements
Access annual & quarterly financial statements for Guardant Health, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $739.02M | $563.95M | $449.54M | $373.65M | $286.73M |
| Cost of Revenue | $289.80M | $227.05M | $156.32M | $122.91M | $92.53M |
| Gross Profit | $449.22M | $336.90M | $293.21M | $250.74M | $194.19M |
| Gross Profit Ratio | 60.79% | 59.74% | 65.23% | 67.11% | 67.73% |
| Research and Development Expenses | $347.75M | $367.19M | $373.81M | $263.22M | $149.86M |
| General and Administrative Expenses | $180.12M | $155.80M | $163.96M | $206.64M | $192.77M |
| Selling and Marketing Expenses | $364.94M | $295.23M | $299.83M | $191.88M | $106.51M |
| Selling General and Administrative Expenses | $545.06M | $451.03M | $463.78M | $398.52M | $299.28M |
| Other Expenses | $- | $83.40M | $-112.56M | $25.18M | $3.64M |
| Operating Expenses | $892.81M | $901.62M | $837.59M | $661.74M | $449.14M |
| Cost and Expenses | $1.18B | $1.13B | $993.92M | $784.65M | $541.68M |
| Interest Income | $53.69M | $35.37M | $6.07M | $3.93M | $10.17M |
| Interest Expense | $2.58M | $2.58M | $2.58M | $2.58M | $4.77M |
| Depreciation and Amortization | $42.39M | $42.88M | $35.96M | $22.27M | $16.07M |
| EBITDA | $-390.12M | $-433.31M | $-614.91M | $-359.62M | $-225.07M |
| EBITDA Ratio | -52.79% | -76.83% | -136.79% | -96.24% | -78.50% |
| Operating Income | $-443.59M | $-564.73M | $-544.38M | $-411.00M | $-254.95M |
| Operating Income Ratio | -60.02% | -100.14% | -121.10% | -110.00% | -88.92% |
| Total Other Income Expenses Net | $8.51M | $85.96M | $-109.07M | $26.53M | $9.05M |
| Income Before Tax | $-435.09M | $-478.76M | $-653.45M | $-384.47M | $-245.90M |
| Income Before Tax Ratio | -58.87% | -84.90% | -145.36% | -102.89% | -85.76% |
| Income Tax Expense | $1.28M | $685.00K | $1.14M | $300.00K | $379.00K |
| Net Income | $-436.37M | $-479.45M | $-654.59M | $-384.77M | $-246.28M |
| Net Income Ratio | -59.05% | -85.02% | -145.61% | -102.98% | -85.89% |
| EPS | $-3.56 | $-4.28 | $-6.41 | $-3.80 | $-2.53 |
| EPS Diluted | $-3.56 | $-4.28 | $-6.41 | $-3.80 | $-2.53 |
| Weighted Average Shares Outstanding | 122.75M | 111.99M | 102.18M | 101.31M | 97.50M |
| Weighted Average Shares Outstanding Diluted | 122.75M | 111.99M | 102.18M | 101.31M | 97.50M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $201.81M | $191.48M | $177.24M | $168.49M | $155.05M | $143.03M | $137.15M | $128.71M | $126.89M | $117.40M | $109.14M | $96.10M | $108.11M | $94.78M | $92.10M | $78.67M | $78.32M | $74.57M | $66.33M | $67.51M |
| Cost of Revenue | $77.59M | $74.49M | $72.42M | $65.30M | $-81.14M | $57.61M | $53.85M | $53.07M | $47.12M | $40.50M | $36.73M | $31.98M | $33.42M | $30.82M | $29.93M | $28.75M | $28.41M | $21.19M | $22.43M | $20.51M |
| Gross Profit | $124.22M | $116.99M | $104.81M | $103.19M | $236.19M | $85.42M | $83.30M | $75.64M | $79.77M | $76.91M | $72.42M | $64.12M | $74.69M | $63.96M | $62.17M | $49.92M | $49.91M | $53.38M | $43.90M | $47.00M |
| Gross Profit Ratio | 61.55% | 61.10% | 59.14% | 61.25% | 152.33% | 59.72% | 60.74% | 58.77% | 62.86% | 65.51% | 66.35% | 66.72% | 69.08% | 67.49% | 67.51% | 63.46% | 63.73% | 71.59% | 66.18% | 69.63% |
| Research and Development Expenses | $93.54M | $87.31M | $83.10M | $83.80M | $89.86M | $93.85M | $90.36M | $93.13M | $106.58M | $100.02M | $85.45M | $81.76M | $73.02M | $70.97M | $63.72M | $55.51M | $40.28M | $36.24M | $36.32M | $37.02M |
| General and Administrative Expenses | $51.88M | $49.13M | $40.46M | $38.65M | $37.66M | $36.17M | $41.52M | $40.45M | $37.89M | $41.12M | $43.68M | $41.27M | $40.27M | $50.05M | $48.38M | $67.94M | $69.50M | $66.29M | $37.19M | $19.79M |
| Selling and Marketing Expenses | $104.76M | $97.88M | $81.87M | $80.42M | $79.13M | $68.93M | $71.04M | $76.12M | $81.42M | $80.37M | $73.60M | $64.43M | $59.60M | $50.23M | $47.72M | $34.34M | $31.29M | $25.09M | $25.02M | $25.11M |
| Selling General and Administrative Expenses | $156.64M | $147.01M | $122.33M | $119.08M | $116.79M | $105.11M | $112.56M | $116.57M | $119.31M | $121.49M | $117.28M | $105.70M | $99.87M | $100.28M | $96.09M | $102.27M | $100.79M | $91.39M | $62.20M | $44.90M |
| Other Expenses | $- | $- | $-15.14M | $-29.12M | $227.05M | $16.89M | $41.26M | $-1.65M | $5.28M | $-18.39M | $-99.41M | $-48.00K | $25.90M | $-187.00K | $-243.00K | $-290.00K | $1.22M | $345.00K | $2.29M | $-209.00K |
| Operating Expenses | $250.19M | $234.31M | $205.43M | $202.88M | $433.70M | $198.96M | $202.92M | $209.70M | $225.89M | $221.51M | $202.74M | $187.46M | $172.89M | $171.25M | $159.82M | $157.78M | $141.07M | $127.63M | $98.52M | $81.92M |
| Cost and Expenses | $327.78M | $308.80M | $277.85M | $268.17M | $352.56M | $256.57M | $256.77M | $262.77M | $273.01M | $262.00M | $239.47M | $219.44M | $206.32M | $202.07M | $189.74M | $186.53M | $169.48M | $148.82M | $120.95M | $102.42M |
| Interest Income | $11.65M | $13.26M | $13.91M | $14.87M | $13.89M | $11.69M | $6.73M | $3.06M | $2.15M | $1.75M | $1.39M | $778.00K | $653.00K | $689.00K | $1.04M | $1.55M | $1.90M | $2.31M | $2.64M | $3.32M |
| Interest Expense | $645.00K | $646.00K | $645.00K | $645.00K | $645.00K | $644.00K | $645.00K | $644.00K | $644.00K | $644.00K | $645.00K | $644.00K | $643.00K | $644.00K | $644.00K | $646.00K | $4.74M | $8.00K | $10.00K | $12.00K |
| Depreciation and Amortization | $10.45M | $10.60M | $10.70M | $10.71M | $10.87M | $11.04M | $10.63M | $10.35M | $10.17M | $9.81M | $8.79M | $7.20M | $6.09M | $5.50M | $5.60M | $5.01M | $4.60M | $967.00K | $5.70M | $4.80M |
| EBITDA | $-99.19M | $-96.48M | $-91.15M | $-103.22M | $-176.07M | $-73.93M | $-61.00M | $-122.30M | $-128.52M | $-151.43M | $-219.56M | $-115.41M | $-65.57M | $-101.29M | $-91.25M | $-101.59M | $-83.44M | $-67.24M | $-44.00M | $-27.00M |
| EBITDA Ratio | -49.15% | -50.39% | -51.43% | -61.26% | -113.55% | -51.69% | -44.48% | -95.02% | -101.28% | -128.98% | -201.16% | -120.09% | -60.65% | -106.87% | -99.07% | -129.15% | -106.55% | -90.17% | -66.33% | -40.00% |
| Operating Income | $-125.97M | $-117.33M | $-100.62M | $-99.68M | $-197.51M | $-113.54M | $-119.62M | $-134.06M | $-146.12M | $-144.60M | $-130.32M | $-123.34M | $-98.21M | $-107.29M | $-97.64M | $-107.86M | $-91.17M | $-74.25M | $-54.62M | $-34.91M |
| Operating Income Ratio | -62.42% | -61.28% | -56.77% | -59.16% | -127.38% | -79.38% | -87.22% | -104.15% | -115.15% | -123.16% | -119.40% | -128.34% | -90.84% | -113.20% | -106.02% | -137.12% | -116.41% | -99.57% | -82.34% | -51.71% |
| Total Other Income Expenses Net | $15.68M | $9.60M | $-1.88M | $-14.90M | $9.93M | $27.93M | $47.34M | $762.00K | $6.79M | $-17.28M | $-98.67M | $86.00K | $25.91M | $-142.00K | $150.00K | $615.00K | $-1.62M | $2.65M | $4.92M | $3.10M |
| Income Before Tax | $-110.29M | $-107.72M | $-102.50M | $-114.58M | $-187.58M | $-85.61M | $-72.28M | $-133.29M | $-139.33M | $-161.88M | $-228.99M | $-123.25M | $-72.30M | $-107.43M | $-97.49M | $-107.25M | $-92.78M | $-71.60M | $-49.70M | $-31.82M |
| Income Before Tax Ratio | -54.65% | -56.26% | -57.83% | -68.00% | -120.98% | -59.86% | -52.70% | -103.56% | -109.80% | -137.88% | -209.80% | -128.26% | -66.88% | -113.35% | -105.85% | -136.34% | -118.47% | -96.02% | -74.93% | -47.13% |
| Income Tax Expense | $716.00K | $30.00K | $133.00K | $405.00K | $-541.00K | $490.00K | $496.00K | $240.00K | $602.00K | $115.00K | $446.00K | $-24.00K | $11.00K | $96.00K | $83.00K | $110.00K | $263.00K | $68.00K | $34.00K | $14.00K |
| Net Income | $-111.01M | $-107.75M | $-102.63M | $-114.98M | $-187.04M | $-86.10M | $-72.77M | $-133.53M | $-139.93M | $-161.99M | $-229.43M | $-123.23M | $-90.91M | $-107.53M | $-97.58M | $-109.66M | $-93.75M | $-77.67M | $-54.64M | $-27.73M |
| Net Income Ratio | -55.00% | -56.28% | -57.91% | -68.24% | -120.63% | -60.20% | -53.06% | -103.74% | -110.28% | -137.98% | -210.21% | -128.23% | -84.09% | -113.45% | -105.94% | -139.40% | -119.70% | -104.16% | -82.37% | -41.07% |
| EPS | $-0.90 | $-0.88 | $-0.84 | $-0.94 | $-1.58 | $-0.73 | $-0.67 | $-1.30 | $-1.36 | $-1.58 | $-2.25 | $-1.21 | $-0.89 | $-1.06 | $-0.96 | $-1.09 | $-0.94 | $-0.78 | $-0.57 | $-0.29 |
| EPS Diluted | $-0.90 | $-0.88 | $-0.84 | $-0.94 | $-1.58 | $-0.73 | $-0.67 | $-1.30 | $-1.36 | $-1.58 | $-2.25 | $-1.21 | $-0.89 | $-1.06 | $-0.96 | $-1.09 | $-0.94 | $-0.78 | $-0.57 | $-0.29 |
| Weighted Average Shares Outstanding | 123.75M | 123.05M | 122.45M | 121.71M | 118.51M | 117.74M | 108.81M | 102.66M | 102.52M | 102.29M | 102.05M | 101.85M | 101.70M | 101.42M | 101.17M | 100.95M | 100.02M | 99.55M | 96.01M | 94.38M |
| Weighted Average Shares Outstanding Diluted | 123.75M | 123.05M | 122.45M | 121.71M | 118.51M | 117.74M | 108.81M | 102.66M | 102.52M | 102.29M | 102.05M | 101.85M | 101.70M | 101.42M | 101.17M | 100.95M | 100.02M | 99.55M | 96.01M | 94.38M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $525.54M | $1.13B | $141.65M | $492.20M | $832.98M |
| Short Term Investments | $314.44M | $35.10M | $869.58M | $440.55M | $961.90M |
| Cash and Short Term Investments | $839.98M | $1.17B | $1.01B | $932.75M | $1.79B |
| Net Receivables | $110.25M | $88.78M | $97.26M | $97.65M | $53.30M |
| Inventory | $71.08M | $61.95M | $51.60M | $30.67M | $22.72M |
| Other Current Assets | $33.80M | $27.74M | $31.51M | $106.10M | $34.93M |
| Total Current Assets | $1.06B | $1.35B | $1.19B | $1.11B | $1.89B |
| Property Plant Equipment Net | $279.08M | $302.71M | $341.92M | $313.90M | $100.12M |
| Goodwill | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M |
| Intangible Assets | $6.76M | $8.98M | $11.73M | $14.21M | $16.20M |
| Goodwill and Intangible Assets | $10.05M | $12.27M | $15.02M | $17.50M | $19.49M |
| Long Term Investments | $- | $150.00K | $300.00K | $698.03M | $246.60M |
| Tax Assets | $- | $- | $-300.00K | $- | $- |
| Other Non-Current Assets | $141.37M | $124.18M | $61.45M | $60.94M | $17.21M |
| Total Non-Current Assets | $430.50M | $439.31M | $418.39M | $1.09B | $383.42M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.49B | $1.79B | $1.61B | $2.20B | $2.27B |
| Account Payables | $38.55M | $51.74M | $68.91M | $17.58M | $7.34M |
| Short Term Debt | $29.21M | $27.95M | $21.88M | $12.86M | $6.63M |
| Tax Payables | $- | $- | $- | $4.22M | $4.63M |
| Deferred Revenue | $35.47M | $17.96M | $17.40M | $11.33M | $8.55M |
| Other Current Liabilities | $122.35M | $108.26M | $85.03M | $148.70M | $39.65M |
| Total Current Liabilities | $225.58M | $205.92M | $193.22M | $194.69M | $66.81M |
| Long Term Debt | $1.31B | $1.33B | $1.35B | $1.36B | $847.86M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $92.83M | $96.01M | $9.18M | $3.93M | $1.52M |
| Total Non-Current Liabilities | $1.40B | $1.42B | $1.36B | $1.36B | $849.38M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $1.63B | $1.63B | $1.55B | $1.56B | $916.19M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K |
| Retained Earnings | $-2.58B | $-2.14B | $-1.66B | $-1.01B | $-606.59M |
| Accumulated Other Comprehensive Income Loss | $-5.20M | $-3.67M | $-19.52M | $-4.76M | $2.70M |
| Other Total Stockholders Equity | $2.44B | $2.30B | $1.74B | $1.66B | $1.90B |
| Total Stockholders Equity | $-139.65M | $158.68M | $60.18M | $645.00M | $1.30B |
| Total Equity | $-139.65M | $158.68M | $60.18M | $723.00M | $1.36B |
| Total Liabilities and Stockholders Equity | $1.49B | $1.79B | $1.61B | $2.20B | $2.27B |
| Minority Interest | $- | $- | $- | $78.00M | $57.10M |
| Total Liabilities and Total Equity | $1.49B | $1.79B | $1.61B | $2.20B | $2.27B |
| Total Investments | $314.44M | $35.25M | $869.58M | $1.14B | $1.21B |
| Total Debt | $1.34B | $1.35B | $1.37B | $1.36B | $847.86M |
| Net Debt | $810.51M | $220.23M | $1.23B | $868.67M | $14.88M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $525.54M | $688.37M | $1.04B | $1.13B | $1.13B | $457.34M | $271.07M | $223.64M | $141.65M | $158.31M | $215.17M | $573.60M | $492.20M | $832.37M | $938.59M | $869.37M | $832.98M | $142.94M | $164.67M | $152.24M |
| Short Term Investments | $314.44M | $310.70M | $52.46M | $- | $35.10M | $697.48M | $953.78M | $713.38M | $869.58M | $799.73M | $638.52M | $388.66M | $440.55M | $653.60M | $853.07M | $1.07B | $961.90M | $870.46M | $773.16M | $367.85M |
| Cash and Short Term Investments | $839.98M | $999.07M | $1.04B | $1.13B | $1.17B | $1.15B | $1.22B | $937.02M | $1.01B | $958.04M | $853.69M | $962.27M | $932.75M | $1.49B | $1.79B | $1.94B | $1.79B | $1.01B | $937.83M | $520.09M |
| Net Receivables | $110.25M | $88.47M | $100.52M | $84.56M | $88.78M | $88.80M | $86.47M | $87.20M | $97.26M | $86.20M | $95.28M | $84.33M | $97.65M | $60.74M | $53.67M | $48.04M | $53.30M | $36.26M | $41.02M | $48.02M |
| Inventory | $71.08M | $72.30M | $66.98M | $62.99M | $61.95M | $77.04M | $60.53M | $46.47M | $51.60M | $63.05M | $59.89M | $36.61M | $30.67M | $24.74M | $26.49M | $28.88M | $22.72M | $27.73M | $20.35M | $25.15M |
| Other Current Assets | $33.80M | $66.88M | $87.23M | $31.74M | $27.74M | $26.24M | $25.81M | $33.76M | $31.51M | $47.13M | $28.28M | $60.14M | $106.10M | $43.92M | $38.47M | $31.36M | $34.93M | $19.80M | $22.20M | $28.27M |
| Total Current Assets | $1.06B | $1.23B | $1.29B | $1.31B | $1.35B | $1.35B | $1.40B | $1.10B | $1.19B | $1.13B | $1.04B | $1.11B | $1.11B | $1.59B | $1.89B | $2.03B | $1.89B | $1.09B | $1.01B | $607.39M |
| Property Plant Equipment Net | $279.08M | $270.13M | $278.43M | $290.27M | $302.71M | $309.34M | $321.01M | $333.88M | $341.92M | $346.75M | $347.06M | $339.93M | $313.90M | $302.59M | $290.69M | $277.44M | $100.12M | $97.98M | $95.50M | $76.82M |
| Goodwill | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M |
| Intangible Assets | $6.76M | $7.25M | $7.74M | $8.29M | $8.98M | $9.67M | $10.36M | $11.05M | $11.73M | $12.42M | $13.11M | $13.73M | $14.21M | $14.70M | $15.19M | $15.67M | $16.20M | $16.70M | $17.20M | $17.74M |
| Goodwill and Intangible Assets | $10.05M | $10.54M | $11.03M | $11.58M | $12.27M | $12.96M | $13.65M | $14.34M | $15.02M | $15.71M | $16.40M | $17.02M | $17.50M | $17.99M | $18.48M | $18.96M | $19.49M | $19.98M | $20.49M | $21.03M |
| Long Term Investments | $- | $- | $11.10M | $76.50M | $150.00K | $24.00K | $101.00K | $74.00K | $300.00K | $156.74M | $382.57M | $588.45M | $698.03M | $250.23M | $55.37M | $- | $246.60M | $51.40M | $146.12M | $238.21M |
| Tax Assets | $- | $- | $- | $-1 | $- | $-24.00K | $-101.00K | $-74.00K | $-300.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $141.37M | $31.34M | $18.81M | $17.70M | $124.18M | $128.03M | $107.70M | $58.95M | $61.45M | $51.73M | $70.56M | $70.92M | $60.94M | $61.32M | $36.28M | $17.30M | $17.21M | $5.45M | $5.12M | $4.72M |
| Total Non-Current Assets | $430.50M | $312.01M | $319.37M | $396.05M | $439.31M | $450.33M | $442.36M | $407.17M | $418.39M | $570.93M | $816.60M | $1.02B | $1.09B | $632.12M | $400.83M | $313.70M | $383.42M | $174.82M | $267.23M | $340.77M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.49B | $1.54B | $1.61B | $1.70B | $1.79B | $1.80B | $1.84B | $1.51B | $1.61B | $1.70B | $1.85B | $2.13B | $2.20B | $2.23B | $2.29B | $2.35B | $2.27B | $1.26B | $1.28B | $948.17M |
| Account Payables | $38.55M | $15.47M | $42.45M | $37.60M | $51.74M | $77.83M | $79.78M | $67.32M | $68.91M | $40.91M | $36.97M | $32.23M | $17.58M | $15.67M | $21.40M | $22.32M | $7.34M | $18.28M | $15.98M | $24.38M |
| Short Term Debt | $29.21M | $27.38M | $27.66M | $27.96M | $27.95M | $26.36M | $24.71M | $23.62M | $21.88M | $20.49M | $19.30M | $16.56M | $12.86M | $8.25M | $7.55M | $7.08M | $6.63M | $7.44M | $8.24M | $7.31M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.56M | $3.22M | $4.40M | $4.22M | $4.08M | $4.50M | $5.12M | $4.63M | $3.75M | $3.27M | $3.36M |
| Deferred Revenue | $35.47M | $29.55M | $29.38M | $22.56M | $17.96M | $21.48M | $12.24M | $13.62M | $17.40M | $13.42M | $14.96M | $10.57M | $11.33M | $7.32M | $8.48M | $8.36M | $8.55M | $7.34M | $11.48M | $11.94M |
| Other Current Liabilities | $122.35M | $124.94M | $102.08M | $131.89M | $108.26M | $101.08M | $84.20M | $99.59M | $85.03M | $96.73M | $93.31M | $165.05M | $148.70M | $66.98M | $54.69M | $52.62M | $39.65M | $35.16M | $31.07M | $35.34M |
| Total Current Liabilities | $225.58M | $197.34M | $201.57M | $220.01M | $205.92M | $226.75M | $200.93M | $204.16M | $193.22M | $175.12M | $167.75M | $228.81M | $194.69M | $102.30M | $96.61M | $95.50M | $66.81M | $71.97M | $70.05M | $82.32M |
| Long Term Debt | $1.31B | $1.31B | $1.31B | $1.32B | $1.33B | $1.33B | $1.34B | $1.34B | $1.35B | $1.35B | $1.36B | $1.36B | $1.36B | $1.35B | $1.35B | $1.34B | $847.86M | $39.68M | $41.12M | $33.77M |
| Deferred Revenue Non-Current | $- | $- | $6.00M | $5.30M | $- | $2.90M | $2.90M | $3.40M | $- | $2.00M | $2.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $172.19M | $178.91M | $- | $-2.90M | $-2.90M | $-3.40M | $- | $-2.00M | $-2.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $92.83M | $89.45M | $95.93M | $91.49M | $96.01M | $10.18M | $9.45M | $9.14M | $9.18M | $6.99M | $9.29M | $6.91M | $3.93M | $3.42M | $2.49M | $1.65M | $1.52M | $1.86M | $1.38M | $1.46M |
| Total Non-Current Liabilities | $1.40B | $1.40B | $1.41B | $1.42B | $1.42B | $1.34B | $1.35B | $1.35B | $1.36B | $1.36B | $1.37B | $1.37B | $1.36B | $1.35B | $1.35B | $1.34B | $849.38M | $41.54M | $42.50M | $35.23M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $1.63B | $1.60B | $1.61B | $1.64B | $1.63B | $1.57B | $1.55B | $1.56B | $1.55B | $1.54B | $1.53B | $1.60B | $1.56B | $1.46B | $1.44B | $1.44B | $916.19M | $113.50M | $112.55M | $117.55M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K |
| Retained Earnings | $-2.58B | $-2.47B | $-2.36B | $-2.26B | $-2.14B | $-1.95B | $-1.87B | $-1.80B | $-1.66B | $-1.52B | $-1.36B | $-1.13B | $-1.01B | $-916.91M | $-809.39M | $-711.81M | $-606.59M | $-512.85M | $-435.18M | $-380.54M |
| Accumulated Other Comprehensive Income Loss | $-5.20M | $-3.28M | $-5.64M | $-4.80M | $-3.67M | $-5.68M | $-8.47M | $-12.15M | $-19.52M | $-26.85M | $-24.26M | $-18.31M | $-4.76M | $-593.00K | $33.00K | $904.00K | $2.70M | $3.86M | $5.39M | $7.71M |
| Other Total Stockholders Equity | $2.44B | $2.41B | $2.36B | $2.33B | $2.30B | $2.19B | $2.17B | $1.76B | $1.74B | $1.72B | $1.70B | $1.68B | $1.66B | $1.63B | $1.60B | $1.56B | $1.90B | $1.60B | $1.54B | $1.16B |
| Total Stockholders Equity | $-139.65M | $-60.10M | $-1.61M | $68.28M | $158.68M | $228.30M | $292.73M | $-44.55M | $60.18M | $166.75M | $319.09M | $533.04M | $645.00M | $709.42M | $788.07M | $847.05M | $1.30B | $1.09B | $1.11B | $785.11M |
| Total Equity | $-139.65M | $-60.10M | $-1.61M | $68.28M | $158.68M | $228.30M | $292.73M | $-44.55M | $60.18M | $166.75M | $319.09M | $611.04M | $723.00M | $768.82M | $847.47M | $906.45M | $1.36B | $1.15B | $1.16B | $830.61M |
| Total Liabilities and Stockholders Equity | $1.49B | $1.54B | $1.61B | $1.70B | $1.79B | $1.80B | $1.84B | $1.51B | $1.61B | $1.70B | $1.85B | $2.13B | $2.20B | $2.23B | $2.29B | $2.35B | $2.27B | $1.26B | $1.28B | $948.17M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $78.00M | $78.00M | $59.40M | $59.40M | $59.40M | $57.10M | $56.40M | $50.40M | $45.50M |
| Total Liabilities and Total Equity | $1.49B | $1.54B | $1.61B | $1.70B | $1.79B | $1.80B | $1.84B | $1.51B | $1.61B | $1.70B | $1.85B | $2.13B | $2.20B | $2.23B | $2.29B | $2.35B | $2.27B | $1.26B | $1.28B | $948.17M |
| Total Investments | $314.44M | $310.70M | $11.10M | $76.50M | $35.25M | $697.48M | $953.78M | $713.38M | $869.58M | $956.47M | $1.07B | $977.12M | $1.14B | $903.83M | $908.44M | $1.07B | $1.21B | $921.86M | $919.28M | $606.06M |
| Total Debt | $1.34B | $1.34B | $1.34B | $1.35B | $1.35B | $1.36B | $1.34B | $1.34B | $1.37B | $1.37B | $1.38B | $1.38B | $1.36B | $1.36B | $1.35B | $1.35B | $847.86M | $47.12M | $41.12M | $41.08M |
| Net Debt | $810.51M | $651.05M | $305.87M | $218.22M | $220.23M | $901.02M | $1.07B | $1.12B | $1.23B | $1.22B | $1.16B | $803.79M | $868.67M | $526.87M | $414.28M | $480.85M | $14.88M | $-95.83M | $-123.55M | $-111.16M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-436.37M | $-479.45M | $-654.59M | $-384.77M | $-246.28M |
| Depreciation and Amortization | $42.39M | $42.88M | $35.96M | $22.27M | $16.07M |
| Deferred Income Tax | $- | $- | $- | $12.90M | $11.17M |
| Stock Based Compensation | $140.41M | $90.76M | $94.69M | $151.45M | $144.11M |
| Change in Working Capital | $- | $53.84M | $61.56M | $-40.47M | $-47.66M |
| Accounts Receivables | $-21.39M | $8.38M | $375.00K | $-44.35M | $-5.46M |
| Inventory | $-9.13M | $-10.35M | $-20.93M | $-7.96M | $-7.54M |
| Accounts Payables | $-2.82M | $88.59M | $60.33M | $8.64M | $-7.86M |
| Other Working Capital | $- | $-32.78M | $21.79M | $3.20M | $-26.81M |
| Other Non Cash Items | $13.72M | $-33.01M | $152.91M | $29.61M | $18.68M |
| Net Cash Provided by Operating Activities | $-239.86M | $-324.98M | $-309.46M | $-209.02M | $-103.93M |
| Investments in Property Plant and Equipment | $-35.09M | $-20.49M | $-77.46M | $-75.03M | $-54.06M |
| Acquisitions Net | $- | $- | $-227.28M | $-11.88M | $17.89M |
| Purchases of Investments | $-314.82M | $-635.50M | $-327.72M | $-940.23M | $-1.13B |
| Sales Maturities of Investments | $88.60M | $1.49B | $555.00M | $952.11M | $562.55M |
| Other Investing Activities | $- | $1.53M | $227.28M | $11.88M | $-17.89M |
| Net Cash Used for Investing Activities | $-261.31M | $840.25M | $149.82M | $-63.16M | $-617.09M |
| Debt Repayment | $- | $- | $-71.00K | $-146.00K | $1.13B |
| Common Stock Issued | $- | $493.12M | $11.94M | $17.86M | $- |
| Common Stock Repurchased | $11.72M | $10.15M | $-7.88M | $-83.76M | $-3.45M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-996.00K | $-15.74M | $-189.02M | $-66.68M | $-78.00M |
| Net Cash Used Provided by Financing Activities | $-996.00K | $477.38M | $-189.09M | $-66.82M | $1.41B |
| Effect of Forex Changes on Cash | $-1.77M | $-911.00K | $-1.60M | $-1.69M | $455.00K |
| Net Change in Cash | $-503.93M | $991.74M | $-842.63M | $-340.69M | $689.75M |
| Cash at End of Period | $629.75M | $1.13B | $-350.34M | $492.29M | $832.98M |
| Cash at Beginning of Period | $1.13B | $141.95M | $492.29M | $832.98M | $143.23M |
| Operating Cash Flow | $-239.86M | $-324.98M | $-309.46M | $-209.02M | $-103.93M |
| Capital Expenditure | $-35.09M | $-20.49M | $-77.46M | $-75.03M | $-54.06M |
| Free Cash Flow | $-274.94M | $-345.46M | $-386.92M | $-284.05M | $-157.99M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-111.01M | $-107.75M | $-102.63M | $-114.98M | $-187.04M | $-86.10M | $-72.77M | $-133.53M | $-139.93M | $-161.99M | $-229.43M | $-123.23M | $-72.31M | $-107.53M | $-97.58M | $-107.36M | $-93.05M | $-71.67M | $-49.74M | $-31.83M |
| Depreciation and Amortization | $10.45M | $10.52M | $10.70M | $10.71M | $10.87M | $11.04M | $10.63M | $10.35M | $10.17M | $9.81M | $8.79M | $7.20M | $6.09M | $5.54M | $5.63M | $5.01M | $4.60M | $967.00K | $5.70M | $4.80M |
| Deferred Income Tax | $- | $- | $- | $- | $66.97M | $-24.46M | $-42.50M | $- | $- | $- | $- | $- | $3.34M | $3.03M | $3.27M | $3.26M | $1.48M | $8.63M | $-1.21M | $580.00K |
| Stock Based Compensation | $36.37M | $49.77M | $27.23M | $27.04M | $24.32M | $21.82M | $22.35M | $22.27M | $23.70M | $20.64M | $25.54M | $24.80M | $26.86M | $35.02M | $34.51M | $55.07M | $56.76M | $55.20M | $25.82M | $6.34M |
| Change in Working Capital | $-2.83M | $45.83M | $-53.70M | $7.87M | $64.17M | $-8.39M | $-20.14M | $18.20M | $11.58M | $27.10M | $-27.27M | $50.16M | $-49.02M | $2.25M | $-16.85M | $23.16M | $-35.97M | $-4.62M | $-5.55M | $-1.54M |
| Accounts Receivables | $-21.70M | $12.05M | $-15.96M | $4.22M | $18.00K | $-2.33M | $-1.65M | $12.35M | $-11.06M | $9.08M | $-10.94M | $13.30M | $-36.91M | $-7.08M | $-5.63M | $5.26M | $-17.04M | $4.69M | $7.07M | $-179.00K |
| Inventory | $1.21M | $-5.31M | $-3.99M | $-1.04M | $15.09M | $-16.50M | $-14.06M | $5.12M | $11.45M | $-3.16M | $-23.28M | $-5.94M | $-5.93M | $1.75M | $2.38M | $-6.16M | $5.01M | $-7.38M | $4.79M | $-9.97M |
| Accounts Payables | $- | $-4.79M | $-28.27M | $13.24M | $62.01M | $1.22M | $-2.52M | $13.89M | $42.58M | $6.66M | $11.84M | $-753.00K | $1.70M | $-173.00K | $-4.87M | $11.99M | $-8.71M | $3.32M | $-11.97M | $9.49M |
| Other Working Capital | $17.66M | $43.88M | $-5.48M | $-8.55M | $-12.95M | $9.22M | $-1.91M | $-13.16M | $-31.39M | $14.52M | $-10.78M | $43.55M | $-7.88M | $7.75M | $-8.73M | $12.07M | $-15.23M | $-5.25M | $-5.45M | $-882.00K |
| Other Non Cash Items | $2.50M | $-49.43M | $121.24M | $71.13M | $-58.01M | $8.31M | $8.42M | $8.28M | $3.73M | $26.29M | $109.09M | $12.45M | $8.06M | $8.54M | $8.43M | $4.57M | $6.95M | $3.44M | $1.62M | $8.37M |
| Net Cash Provided by Operating Activities | $-64.51M | $-51.06M | $-94.00M | $-30.28M | $-78.73M | $-77.79M | $-94.02M | $-74.44M | $-90.75M | $-78.16M | $-111.94M | $-28.62M | $-76.99M | $-53.15M | $-62.59M | $-16.29M | $-59.22M | $-8.06M | $-23.36M | $-13.28M |
| Investments in Property Plant and Equipment | $-18.88M | $-4.20M | $-5.08M | $-6.93M | $-4.08M | $-2.37M | $-6.51M | $-7.52M | $-10.00M | $-21.73M | $-23.03M | $-22.70M | $-24.62M | $-22.15M | $-18.68M | $-9.59M | $-7.28M | $-9.79M | $-9.51M | $-27.48M |
| Acquisitions Net | $- | $- | $- | $- | $- | $-263.07M | $234.61M | $-164.75M | $-80.63M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $17.89M |
| Purchases of Investments | $-5.00M | $-309.82M | $- | $- | $- | $-72.93M | $-499.31M | $-63.25M | $-76.37M | $- | $-74.86M | $-176.49M | $-567.07M | $-234.25M | $-68.26M | $-70.65M | $-545.40M | $-114.87M | $-409.54M | $-55.76M |
| Sales Maturities of Investments | $34.41M | $19.20M | $- | $35.00M | $666.00M | $336.00M | $264.70M | $228.00M | $157.00M | $63.00M | $25.00M | $310.00M | $325.00M | $209.00M | $214.00M | $204.11M | $255.00M | $110.00M | $93.50M | $104.05M |
| Other Investing Activities | $- | $- | $- | $35.00M | $1.53M | $263.07M | $-234.61M | $164.75M | $80.63M | $63.00M | $-49.86M | $133.51M | $-242.07M | $-25.25M | $145.74M | $133.46M | $-290.40M | $-4.87M | $-316.04M | $-17.89M |
| Net Cash Used for Investing Activities | $10.53M | $-294.83M | $-5.08M | $28.07M | $663.45M | $260.70M | $-241.13M | $157.22M | $70.63M | $41.27M | $-72.89M | $110.81M | $-266.70M | $-47.39M | $127.07M | $123.87M | $-297.69M | $-14.66M | $-325.55M | $20.80M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $-18.00K | $- | $-18.00K | $-17.00K | $-18.00K | $- | $-38.00K | $-36.00K | $-55.00K | $-49.00K | $-46.00K | $-41.00K | $-38.00K |
| Common Stock Issued | $- | $-9.79M | $9.58M | $213.00K | $90.62M | $7.56M | $- | $157.00K | $- | $347.00K | $6.94M | $963.00K | $6.18M | $1.68M | $6.33M | $3.68M | $-359.99M | $- | $359.69M | $- |
| Common Stock Repurchased | $- | $1.54M | $7.21M | $-1.54M | $- | $-3.00M | $-4.12M | $-993.00K | $-1.36M | $-4.34M | $-1.22M | $-957.00K | $-1.60M | $-7.20M | $-1.38M | $-73.58M | $7.09M | $-2.25M | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $-21.19M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.49B | $- | $- | $- |
| Other Financing Activities | $-2.94M | $-2.88M | $5.90M | $-1.07M | $-48.00K | $3.81M | $387.97M | $-836.00K | $3.68M | $-19.29M | $-172.07M | $6.00K | $3.78M | $-5.52M | $4.95M | $-69.90M | $1.05B | $843.00K | $1.68M | $1.50M |
| Net Cash Used Provided by Financing Activities | $-2.94M | $-2.88M | $5.90M | $-1.07M | $90.57M | $3.81M | $383.85M | $-854.00K | $2.32M | $-19.31M | $-172.09M | $-12.00K | $3.78M | $-5.56M | $4.91M | $-69.95M | $1.05B | $797.00K | $361.32M | $1.47M |
| Effect of Forex Changes on Cash | $-1.70M | $1.90M | $-837.00K | $-1.14M | $1.03M | $-526.00K | $-1.25M | $-163.00K | $1.14M | $-529.00K | $-1.42M | $-792.00K | $-500.00K | $-113.00K | $7.00K | $-1.09M | $216.00K | $190.00K | $26.00K | $23.00K |
| Net Change in Cash | $-58.61M | $-346.87M | $-94.02M | $-4.28M | $676.20M | $186.19M | $47.46M | $81.77M | $-175.28M | $-56.73M | $-358.33M | $81.39M | $-340.40M | $-106.21M | $69.39M | $36.54M | $690.03M | $-21.73M | $12.43M | $9.01M |
| Cash at End of Period | $629.75M | $688.37M | $1.04B | $1.13B | $1.13B | $457.36M | $271.17M | $223.71M | $-16.66M | $158.61M | $215.34M | $573.67M | $492.29M | $832.69M | $938.90M | $869.52M | $832.98M | $142.94M | $164.67M | $152.24M |
| Cash at Beginning of Period | $688.37M | $1.04B | $1.13B | $1.13B | $457.34M | $271.17M | $223.71M | $141.95M | $158.61M | $215.34M | $573.67M | $492.29M | $832.69M | $938.90M | $869.52M | $832.98M | $142.94M | $164.67M | $152.24M | $143.23M |
| Operating Cash Flow | $-64.51M | $-51.06M | $-94.00M | $-30.28M | $-78.73M | $-77.79M | $-94.02M | $-74.44M | $-90.75M | $-78.16M | $-111.94M | $-28.62M | $-76.99M | $-53.15M | $-62.59M | $-16.29M | $-59.22M | $-8.06M | $-23.36M | $-13.28M |
| Capital Expenditure | $-18.88M | $-4.20M | $-5.08M | $-6.93M | $-4.08M | $-2.37M | $-6.51M | $-7.52M | $-10.00M | $-21.73M | $-23.03M | $-22.70M | $-24.62M | $-22.15M | $-18.68M | $-9.59M | $-7.28M | $-9.79M | $-9.51M | $-27.48M |
| Free Cash Flow | $-83.39M | $-55.26M | $-99.08M | $-37.22M | $-82.81M | $-80.16M | $-100.53M | $-81.97M | $-100.75M | $-99.89M | $-134.97M | $-51.32M | $-101.61M | $-75.29M | $-81.27M | $-25.88M | $-66.50M | $-17.84M | $-32.87M | $-40.77M |
Guardant Health Dividends
Explore Guardant Health's dividend history, including dividend yield, payout ratio, and historical payments.
Guardant Health News
Read the latest news about Guardant Health, including recent articles, headlines, and updates.
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity™ smart liquid biopsy platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25-30 in Chicago. Key data that will be highlighted include: An oral presentation.
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will.
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement with Bayshore HealthCare, a leading home and community healthcare service provider in Canada, to offer Guardant's portfolio of precision oncology tests across the continuum of cancer care through the Bayshore network of clinics in Canada. Bayshore HealthCare provides care to over 350,000 Canadians annually (excluding Quebec), and the agre.
4 Healthcare Stocks With Massive Gains—and More to Come
The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far.
Guardant Health's Shield Blood Test Now Covered for VA Community Care Beneficiaries
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA) as an in-network benefit, with no copay for average-risk individuals who are age 45 or older. Following Medicare.
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation
Guardant Health basically leads in liquid biopsy oncology diagnostics using genomic and digital technologies for early cancer detection. One of its main offerings is Guardant360, which is currently generating record revenues and growth for GH. Similarly, GH has an expanding pipeline, which includes its Reveal and Shield tests, that could significantly boost its future market potential.
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.'s GH Shield blood test for colorectal cancer (CRC) screening.
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 110,681 shares of its common stock to 102 new non-executive employees and one non-qualified stock option award to purchase 22,091 shares of its common stock to one new non-executive employee with a grant date of Febr.
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insights” survey, which showed that nine out of ten physicians surveyed are concerned about the percentage of their patients who do not complete colorectal cancer (CRC) screening. In many cases, this is due to patient fear and anxiety, but a blood test option offers hope to increase screening rates. Conduct.
Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:31 PM ET Guardant Health, Inc. (NASDAQ:GH ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President, IR Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Bill Bonello - Craig-Hallum Tycho Peterson - Jefferies Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Mark Massaro - BTIG Patrick Donnelly - Citi Dan Arias - Stifel Tejas Savant - Morgan Stanley Rachel Vatnsdal - JPMorgan Kyle Mikson - Canaccord Mason Carrico - Stephens Inc. Matt Sykes - Goldman Sachs Operator Good afternoon. Thank you for attending today's Guardant Health Q4 2024 Earnings Call.
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exploring Analyst Estimates for Guardant Health (GH) Q4 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Guardant Health (GH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity
Blood-based cancer testing presents a large opportunity, that is now being realized, with the proliferation of MRD and screening tests. While there is significant competition, and the market winners are yet to be determined, Guardant Health is well positioned. Guardant has faced skepticism due to its large losses and the questionable efficacy of blood-based CRC screening tests.
Here's Why Guardant Health (GH) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Guardant Health (GH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th TD Cowen 45th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4th at 10:30 a.m. Eastern Tim.
Guardant Health Announces Debt Exchange Transactions
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its outstanding 0% Convertible Senior Notes due 2027 (the “2027 Notes”), pursuant to which the Company will issue $600 million aggregate principal amount of 1.25% Convertible Senior Notes due 2031 (the “New Notes”) in exchange for the ret.
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com.
Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showcasing the benefits of Guardant's precision oncology tools across cancer screening, recurrence monitoring, treatment selection and therapy development at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, January 23-25, 2025. Key focus areas in Guardant'.
Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test
On Tuesday, Guardant Health, Inc. GH announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy.
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test. The post Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone appeared first on Investor's Business Daily.
Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
PALO ALTO, Calif., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration agreement that allows biopharmaceutical companies to access the first multi-modal real-world data (RWD) that integrates comprehensive patient electronic medical record (EMR) data with both genomic and epigenomic tumor profiling information across.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for GH.